 |
 |
 |
| |
ID Week 2025
October 19-22
Atlanta, GA
|
| |
| |
- PREFER-LA: People with HIV (PWH) in the United States
with Prior Adherence Challenges with Oral Antiretroviral
Therapy (ART) Prefer Cabotegravir + Rilpivirine Long-Acting
(CAB+RPV LA) Therapy After Switch - (11/04/25)
 
- Real-World Persistence to Long-Acting Cabotegravir Versus Oral PrEP for HIV Prevention in Participants Using a Digital Health Companion Tool (AURORA Study) - (11/04/25)
 
- Rapid Point-of-Care Hepatitis C RNA Test-to-Treat in Persons Experiencing Homelessness through Street Based Initiatives in Detroit, Michigan - (11/04/25)
 
- Low Hepatocellular Carcinoma Surveillance Among Cirrhotic Patients in a Mobile and Telehealth HCV Elimination Program - (11/04/25)
 
- Hepatitis C virus treatment during pregnancy using glecaprevir/pibrentasvir - (11/04/25)
 
- Safety, Tolerability, and Outcomes of SofosbuviR/Velpatasvir in Treatment of Chronic Hepatitis C Virus during Pregnancy: Interim results from the STORC study - (11/04/25)
 
-
Hepatitis C treatment during pregnancy
Implementation of a shared decision-making care model - (11/04/25)
 
-
Integrated Obstetric and Addiction Care Promotes Antepartum STI Screening and Poses Opportunities for Preventing the Vertical Transmission of HIV, HCV, and Syphilis - (11/04/25)
 
-
Hepatitis C Virus Care Continuum Among People Who Inject Drugs - (11/04/25)
 
-
Influence of Nucleos(t)ide Analogue Use With
Bulevirtide on Treatment Outcomes in Chronic Hepatitis Delta - (11/04/25)
 
- Updates on Long COVID Therapeutics - (11/04/25)
 
- Home CAB/RPV Provides Novel Approach to Achieve
Viral Suppression in PWH With Adherence Challenges - (11/02/25)
 
- Acceptability, Feasibility and Appropriateness of the Mobile Outreach Retention and Engagement (MORE) Program and Home Long-Acting Cabotegravir/Rilpivirine (CAB+RPV LA) Injections for People with HIV (PWH) Experiencing Adherence Challenges at Whitman-Walker Health in Washington D.C - (11/02/25)
 
- Effect of Hospitalization on Cognitive Function in People with HIV - (11/02/25)
 
- The Association of Steatotic Liver Disease [fatty liver] and Cardiovascular Disease Risk in a Large Cohort of People with Human Immunodeficiency Virus - (10/31/25)
 
- Low Statin Use in Bronx, NY: OPTIMIZING STATIN USE FOR PRIMARY PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN PEOPLE LIVING WITH HIV - (10/31/25)
 
- Change in Utilization of Statin Therapy Among People with HIV with the Recent Guideline Changes at a Ryan White Clinic in New Orleans, Louisiana - (10/31/25)
 
- PERFORMANCE OF ANTHROPOMETRIC MEASURES FOR
SCREENING EXCESS VISCERAL ADIPOSE TISSUE IN WOMEN WITH HIV - (10/31/25)
 
- Evaluation of Treatment Satisfaction and Experiences Among People With HIV When Switching to B/F/TAF From CAB + RPV: Results From the Phase 4 EMPOWER Study - (10/31/25)
 
- A New Model of HIV Disease Progression Based on the Accumulation of Non-AIDS Comorbidities - (10/31/25)
 
- Frailty PWH in India
- (10/31/25)
 
- On-time Injection Adherence and Persistence
Among People with HIV Engaged in Primary Care on
Long-Acting Cabotegravir/Rilpivirine - (10/31/25)
 
- Evaluation of Treatment Satisfaction and Experiences Among People With HIV When Switching to B/F/TAF From CAB + RPV: Results From the Phase 4 EMPOWER Study - (10/31/25)
 
- A Phase 4 Study to Evaluate the Safety and
Efficacy of Oral B/F/TAF After Discontinuing Injectable CAB + RPV - (10/31/25)
 
- Lenacapavir Adherence and Effectiveness Over 2 Years of Use in the OPERA Cohort - (10/30/25)
 
-
Few differences in persistence and virologic outcomes across age groups among CAB+RPV LA users: Findings from the OPERA Cohort - (10/30/25)
 
- Real-World Insights of the Financial Metrics of a Long-Acting Injectable CAB/RPV Program - (10/30/25)
 
-
Zoster Vaccination in People Living with HIV Is
Associated with Reduced Mortality and Cardiovascular Risk:
A Real-World Matched Cohort Study Zoster Infection &
Vaccination as Determinants of Vascular and Cognitive Outcomes in PLWH - (10/30/25)
 
- Virologic Outcomes with Lenacapavir in Heavily Treatment-Experienced People with HIV: A Multi-Center Real-World Study - (10/30/25)
 
-
Human Immunodeficiency Virus (HIV) Testing and Evidence of HIV Among Real-World Long-Acting Pre-Exposure Prophylaxis (PrEP) Users in a United States Claims Database: Results From the PrEPFACTS Study - (10/30/25)
 
- Frailty in Older People with HIV - (10/30/25)
 
- Changes in Neurocognition and Mood in People Aging with HIV - (10/30/25)
 
- Clinical Outcomes of Long-Acting CAB+RPV in People with HIV Aged 60 and Older - (10/30/25)
 
- Safety and Effectiveness of Long-Acting Cabotegravir/Rilpivirine
in People with HIV and Severe Renal Impairment (CAPRI) - (10/30/25)
 
-
The US REGAL Cohort: A Retrospective Real-world Study of the Effectiveness and Tolerability of the Antiretroviral Treatment Regimens DTG/3TC Compared to BIC/FTC/TAF in Older Persons Living with HIV - (10/30/25)
 
- The Global REGAL Cohort: A Retrospective Real-world Study of the Effectiveness and Tolerability of the Antiretroviral Treatment Regimens DTG/3TC Compared to BIC/FTC/TAF in Older Persons Living With HIV - (10/30/25)
 
- Characterizing Substance Use in Older Adults Living with HIV - (10/29/25)
 
-
High Prevalence of Chemsex in PrEP Users in Buenos Aires, Argentina - (10/29/25)
 
- Polypharmacy, Drug-Drug Interactions, and Risk of Hospitalization [deaths, comorbidities, blacks, linked] among Veterans with HIV Taking 2-, 3-, and 4-Drug Antiretroviral Therapy Regimens - (10/29/25)
 
- TESAMORELIN (EGRIFTA WR AND EGRIFTA® ) FORMULATIONS: BIOEQUIVALENCE IN HEALTHY PARTICIPANTS - (10/29/25)
 
- Healthcare Utilization and Costs in People Living with HIV and Cardiovascular Disease in the United States - (10/29/25)
 
- Healthcare Utilization and Costs in People Living with HIV
and Neuropsychiatric Disorders in the United States; associated
with higher comorbidities rates - (10/29/25)
 
- Effectiveness of Doxycycline Post-Exposure Prophylaxis for STI Prevention in HIV-Positive Individuals: A Two-Year Retrospective Study From the Brooklyn HEAT Clinic - (10/29/25)
 
- Association of HIV Pre-exposure Prophylaxis Initiation and Persistence with Prior Visit with the PrEP Prescriber Among Cisgender Women in the Bronx, NY, 2012-2023 - (10/29/25)
 
- Global survey reveals the ongoing impact of long COVID-19
on medically vulnerable populations, five years on - (10/29/25)
 
-
Oral Weekly Islatravir + Lenacapavir, Efficacy, PK- Update - (10/27/25)
 
- IN-PATIENT MORTALITY TRENDS CAUSED BY HIV INFECTION IN THE UNITED STATES: A RETROSPECTIVE NATIONAL DATABASE HEALTHCARE RESOURCE UTILIZATION ANALYSIS FROM 2016-2022 - (10/29/25)
 
- Hospitalization Patterns and ART Use Among Insured Adults with HIV in the United States, 2016-2021 - (10/29/25)
 
- No Clinically Significant Drug-Drug Interactions With Coadministration of Feminizing or Masculinizing Hormone Therapy and Twice-Yearly Lenacapavir PrEP in Gender-Diverse Persons - (10/29/25)
 
-
PrEP Utilization Patterns and Indications in a Cohort of HIV-Negative Individuals - (10/29/25)
 
- Real-World Sexually Transmitted Infection Testing Patterns Among Individuals Using Pre-Exposure Prophylaxis for HIV-1 Prevention in the United States - (10/29/25)
 
- Phase 2 Pharmacokinetics and Anti-Drug Antibody Results of the Investigational Twice-Yearly HIV-1 Treatment Regimen Lenacapavir, Teropavimab, and Zinlirvimab - (10/28/25)
 
-
Pooled Safety and Tolerability of Twice-yearly
Lenacapavir with Teropavimab and Zinlirvimab For HIV-1 Treatment - (10/28/25)
 
- Evaluation of Relative Bioavailability and Food Effect
of a Fixed-Dose Combination Tablet of Islatravir and Lenacapavir - (10/28/25)
 
- Prevalence of Integrase HIV-1 Drug Resistance Mutations in the United States: 2019-2024 - (10/28/25)
 
-
Efficacy and Safety by Age After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results From Two Phase 3 Randomized, Active-Controlled Studies in Adults Living With HIV-1 - (10/23/25)
 
- Favorable Adherence and Safety of Twice-Yearly Subcutaneous Lenacapavir for PrEP Among PURPOSE 2 Participants Who Used Substances - (10/23/25)
 
- PREFER-LA: People with HIV (PWH) in the United States with Prior Adherence Challenges with Oral Antiretroviral Therapy (ART) Prefer Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA) Therapy After Switch - (10/23/25)
 
- Improved Adherence and Viral Control in Real-World Study of People with HIV (PWH) in the United States with Adherence Challenges on Oral Antiretroviral Therapy (ART) Switching to Cabotegravir + Rilpivirine Long-Acting (CAB+RPV LA). - (10/23/25)
 
- Efficacy and Safety by Sex Assigned at Birth After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results From Two Phase 3 Randomized, Active-Controlled Studies in Adults Living With HIV-1 - (10/23/25)
 
- Safety and Efficacy of Doravirine/Islatravir (DOR/ISL) 100/0.25 mg Once Daily (QD) After ISL Dose Reduction From 0.75 mg: Week 48 Results From an Open-Label Phase 3 Study - (10/23/25)
 
- Switching to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily Maintains Viral Suppression Through Week 48 in the Presence of Archived NNRTI Resistance-Associated Mutations and/or M184I/V in Proviral DNA - (10/23/25)
 
- Modeling Confirms Islatravir 0.25 mg Administered Daily Has No Adverse Effect on Total Lymphocyte or CD4+ T-Cell Counts in People Living With HIV - (10/23/25)
 
- Modeling Confirms Islatravir 0.25 Administered Daily
Has No Adverse Effect on Total Lymphocyte or CD4+ T-Cell Counts in PLWH - (10/23/25)
 
- Population Pharmacokinetic Analysis of Islatravir
and the Impact of Intrinsic Factors in Participants With HIV-1 - (10/23/25)
 
- ViiV Healthcare showcases breadth of clInIcal and real-world evIdence at EACS and IDWeek 2025 - (10/09/25)
 
|
|
| |
|
 |
 |
|
 |
|